Yunfeng Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yunfeng Zheng has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Peng Jiang
The First Affiliated Hospital of Chongqing Medical University
7 shared publications Chenfan Tian
Department of Obstetrics and Gynecology, Chongqing Key Laboratory of Maternal and Fetal Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
6 shared publications- Rui Yuan
The First Affiliated Hospital of Chongqing Medical University
5 shared publications Fan Yang
Centre for Lipid Research & Chongqing Key Laboratory of Metabolism on Lipid and Glucose, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
4 shared publicationsYuan Tu
Department of Obstetrics and Gynecology, Chongqing Key Laboratory of Maternal and Fetal Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
4 shared publicationsChunxia Gong
Department of Obstetrics and Gynecology Women and Children's Hospital of Chongqing Medical University Yubei Chongqing China
3 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Wiley in Advanced Science
A Metabolic‐Epigenetic Axis of AARS1/IGF2BP3‐K280 Lactylation Sustains Endometrial Cancer Stemness and Recurrence
Endometrial cancer (EC) recurrence is strongly associated with enhanced tumor stemness. While lactate—a major tumor‐derived metabolite—is known to promote immunosuppression across cancers, its contribution to EC stemness and recurrence remains poorly understood. In this study, we show that elevated protein lactylation in EC correlates with heightened tumor stemness and unfavorable prognosis. Mechanistically, a lactate‐enriched microenvironment induces lactylation of insulin‐like growth factor 2 mRNA‐binding protein 3 (IGF2BP3), thereby stabilizing and upregulating the protein. This modification enhances EC stemness by enabling IGF2BP3 to stabilize HMGA2 mRNA via an m6A‐dependent pathway, activating downstream stemness‐related transcriptional programs. This effect requires lysine 280 (K280) lactylation mediated by alanyl‐tRNA synthetase 1 (AARS1), as either AARS1 depletion or IGF2BP3‐K280 mutation abolishes lactylation and attenuates stemness. Both genetic and pharmacologic inhibition of IGF2BP3 lactylation markedly suppress tumor growth and stem‐like properties in vitro and in vivo. Clinically, IGF2BP3‐K280 lactylation correlates with aggressive clinicopathological features and poor survival, outperforming conventional biomarkers in recurrence prediction. Integration of IGF2BP3‐K280 lactylation into a clinical nomogram substantially improved recurrence‐risk stratification across multi‐center cohorts. Collectively, these findings uncover a metabolic–epigenetic mechanism linking lactate metabolism to m6A‐mediated stemness regulation, establishing IGF2BP3‐K280 lactylation as both a therapeutic vulnerability and a precision biomarker for EC recurrence.
- 23 September 2026
- Published by Wiley in Advanced Science
Open AccessA Metabolic‐Epigenetic Axis of AARS1/IGF2BP3‐K280 Lactylation Sustains Endometrial Cancer Stemness and Recurrence
Endometrial cancer (EC) recurrence is strongly associated with enhanced tumor stemness. While lactate—a major tumor‐derived metabolite—is known to promote immunosuppression across cancers, its contribution to EC stemness and recurrence remains poorly understood. In this study, we show that elevated protein lactylation in EC correlates with heightened tumor stemness and unfavorable prognosis. Mechanistically, a lactate‐enriched microenvironment induces lactylation of insulin‐like growth factor 2 mRNA‐binding protein 3 (IGF2BP3), thereby stabilizing and upregulating the protein. This modification enhances EC stemness by enabling IGF2BP3 to stabilize HMGA2 mRNA via an m6A‐dependent pathway, activating downstream stemness‐related transcriptional programs. This effect requires lysine 280 (K280) lactylation mediated by alanyl‐tRNA synthetase 1 (AARS1), as either AARS1 depletion or IGF2BP3‐K280 mutation abolishes lactylation and attenuates stemness. Both genetic and pharmacologic inhibition of IGF2BP3 lactylation markedly suppress tumor growth and stem‐like properties in vitro and in vivo. Clinically, IGF2BP3‐K280 lactylation correlates with aggressive clinicopathological features and poor survival, outperforming conventional biomarkers in recurrence prediction. Integration of IGF2BP3‐K280 lactylation into a clinical nomogram substantially improved recurrence‐risk stratification across multi‐center cohorts. Collectively, these findings uncover a metabolic–epigenetic mechanism linking lactate metabolism to m6A‐mediated stemness regulation, establishing IGF2BP3‐K280 lactylation as both a therapeutic vulnerability and a precision biomarker for EC recurrence.
- Open Access
- 7 September 2026
- Published by Springer Nature in Scientific Reports
Prognostic nomogram incorporating dynamic SIRI score and clinical parameters to predict postoperative recurrence of endometrial cancer
- 7 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessPrognostic nomogram incorporating dynamic SIRI score and clinical parameters to predict postoperative recurrence of endometrial cancer
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 10559-10572
Nomogram Incorporating Inflammatory Index, Pathology, and Molecular Classification for Predicting Recurrence in Patients with Stage I-III Endometrial Cancer: A Multi-Institutional Study
Background: This study evaluated the prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score for postoperative recurrence in endometrial cancer patients. A nomogram was developed based on clinicopathological parameters, HALP score, and immunohistochemical markers to predict recurrence-free survival (RFS) in patients with stage I–III endometrial cancer. Methods: This retrospective study included 1,083 patients who underwent hysterectomy at the First Affiliated Hospital of Chongqing Medical University from January 2013 to January 2021. Independent risk factors for RFS were identified using univariate and multivariate Cox regression analyses, and a nomogram was established. External validation was performed with data from Zhujiang Hospital of Southern Medical University and Women and Children’s Hospital of Chongqing Medical University (n = 677). Results: Among the entire cohort, 241 cases (13.7%) of endometrial cancer experienced recurrence post-hysterectomy. The median RFS time was 47.0 (range: 6.0– 91.0) months. Eleven independent prognostic factors were identified, including age, FIGO staging, histologic type, myometrial invasion, lymphovascular space invasion, Ca125, Ki-67 expression, ER expression, molecular classification, adjuvant therapy, and HALP score, and then a nomogram for predicting recurrence of endometrial cancer was established. The nomogram demonstrated improved predictive accuracy, categorizing patients into high- and low-risk groups. High-risk patients receiving adjuvant treatment had better outcomes than those who did not. Conclusion: We developed and validated a nomogram to predict recurrence in endometrial cancer patients. Integrating the HALP score can help clinicians identify high-risk patients and tailor personalized treatment strategies.
- 1 August 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 10559-10572
Open AccessNomogram Incorporating Inflammatory Index, Pathology, and Molecular Classification for Predicting Recurrence in Patients with Stage I-III Endometrial Cancer: A Multi-Institutional Study
Background: This study evaluated the prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score for postoperative recurrence in endometrial cancer patients. A nomogram was developed based on clinicopathological parameters, HALP score, and immunohistochemical markers to predict recurrence-free survival (RFS) in patients with stage I–III endometrial cancer. Methods: This retrospective study included 1,083 patients who underwent hysterectomy at the First Affiliated Hospital of Chongqing Medical University from January 2013 to January 2021. Independent risk factors for RFS were identified using univariate and multivariate Cox regression analyses, and a nomogram was established. External validation was performed with data from Zhujiang Hospital of Southern Medical University and Women and Children’s Hospital of Chongqing Medical University (n = 677). Results: Among the entire cohort, 241 cases (13.7%) of endometrial cancer experienced recurrence post-hysterectomy. The median RFS time was 47.0 (range: 6.0– 91.0) months. Eleven independent prognostic factors were identified, including age, FIGO staging, histologic type, myometrial invasion, lymphovascular space invasion, Ca125, Ki-67 expression, ER expression, molecular classification, adjuvant therapy, and HALP score, and then a nomogram for predicting recurrence of endometrial cancer was established. The nomogram demonstrated improved predictive accuracy, categorizing patients into high- and low-risk groups. High-risk patients receiving adjuvant treatment had better outcomes than those who did not. Conclusion: We developed and validated a nomogram to predict recurrence in endometrial cancer patients. Integrating the HALP score can help clinicians identify high-risk patients and tailor personalized treatment strategies.
- Open Access
- 11 May 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-15
Comparing survival outcomes between surgical and non-surgical treatments in patients with early-onset endometrial cancer and developing a nomogram to predict survival: a study based on Eastern and Western data sets
Background: Surgery is the preferred approach for treating endometrial cancer (EC). However, the prognosis of young women undergoing surgery has not been thoroughly evaluated. This study aims to establish a prognostic nomogram for predicting overall survival (OS) in postoperative patients with early-onset endometrial cancer (EOEC), facilitating risk stratification for high-risk patients. Methods: Patients diagnosed with EOEC during 2004–2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The nomogram of OS was established according to the multivariate Cox regression analyses. The prediction accuracy and clinical net benefit of the model were assessed by the concordance index (C-index), receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Additionally, external validation was performed with 230 EOEC patients who underwent primary surgical treatment at the First Affiliated Hospital of Chongqing Medical University from 2013 to 2018. Results: The mean survival period in the surgical group of EOEC was 87.62 months (range: 86.92–88.32), compared to 64.00 months (range: 55.05–72.96) in the non-surgical group. Compared with the non-surgical group, patients who underwent surgery had better outcomes. A total of 4345 eligible postoperative patients with EOEC were identified and enrolled in this study. Multivariate Cox analysis showed that age, race, grade, T stage, tumor size, and lymphadenectomy were significantly associated with the prognosis of EOEC, which were further incorporated to construct a nomogram. C-index and DCA showed the predictive capability and the clinical applicability of the nomogram was superior over the TNM stage and SEER stage. Furthermore, the external validation using the FAHCQMU cohort consistently demonstrated good predictive accuracy. Conclusions: Generally, we developed a novel nomogram model by comprehensively integrating multiple risk factors, which accurately predicts the clinical prognosis of EOEC patients after surgery.
- 11 May 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-15
Open AccessComparing survival outcomes between surgical and non-surgical treatments in patients with early-onset endometrial cancer and developing a nomogram to predict survival: a study based on Eastern and Western data sets
Background: Surgery is the preferred approach for treating endometrial cancer (EC). However, the prognosis of young women undergoing surgery has not been thoroughly evaluated. This study aims to establish a prognostic nomogram for predicting overall survival (OS) in postoperative patients with early-onset endometrial cancer (EOEC), facilitating risk stratification for high-risk patients. Methods: Patients diagnosed with EOEC during 2004–2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The nomogram of OS was established according to the multivariate Cox regression analyses. The prediction accuracy and clinical net benefit of the model were assessed by the concordance index (C-index), receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Additionally, external validation was performed with 230 EOEC patients who underwent primary surgical treatment at the First Affiliated Hospital of Chongqing Medical University from 2013 to 2018. Results: The mean survival period in the surgical group of EOEC was 87.62 months (range: 86.92–88.32), compared to 64.00 months (range: 55.05–72.96) in the non-surgical group. Compared with the non-surgical group, patients who underwent surgery had better outcomes. A total of 4345 eligible postoperative patients with EOEC were identified and enrolled in this study. Multivariate Cox analysis showed that age, race, grade, T stage, tumor size, and lymphadenectomy were significantly associated with the prognosis of EOEC, which were further incorporated to construct a nomogram. C-index and DCA showed the predictive capability and the clinical applicability of the nomogram was superior over the TNM stage and SEER stage. Furthermore, the external validation using the FAHCQMU cohort consistently demonstrated good predictive accuracy. Conclusions: Generally, we developed a novel nomogram model by comprehensively integrating multiple risk factors, which accurately predicts the clinical prognosis of EOEC patients after surgery.
- Open Access
- 16 December 2024
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 40 (1) , 3-11
LRP1B mutation is associated with lymph node metastasis in endometrial carcinoma: A clinical next-generation sequencing study
Background: This study aims to investigate the mutation status and protein expression of low-density lipoprotein receptor-related protein 1B (LRP1B) in endometrial cancer, and analyze its association with lymph node metastasis (LNM) in endometrial cancer. Methods: Targeted next-generation sequencing (NGS) was conducted on both tumor tissues and paired blood DNA obtained from 94 endometrial cancer patients, followed by comprehensive analysis. Additionally, immunohistochemistry (IHC) was used to explore the correlation between LRP1B protein expression levels, its gene mutation status, and LNM. Results: LRP1B mutation was observed in 19 patients (20.2%). Our results revealed that LRP1B mutation frequencies were significantly different between endometrial cancer with or without LNM ( P = 0.038). Multivariate analysis indicated that LRP1B mutation was a favorable predictor (odds ratio 0.09; 95% confidence interval 0.01–0.95; P = 0.045) for LNM in endometrial cancer. Further analysis revealed that combination of LRP1B mutation with clinical variants (LVSI and histological subtype) yielded a higher area under the curve value of 0.871) and patients harboring LRP1B mutated-type were less likely to develop LNM. On integrated analysis, the concordance between LRP1B NGS and LRP1B IHC was 73.3%. Conclusions: This study utilizes targeted NGS to uncover the relationship between LRP1B mutation and LNM status, contributing to the development of primary prevention and proactive treatment strategies.
- 16 December 2024
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 40 (1) , 3-11
Open AccessLRP1B mutation is associated with lymph node metastasis in endometrial carcinoma: A clinical next-generation sequencing study
Background: This study aims to investigate the mutation status and protein expression of low-density lipoprotein receptor-related protein 1B (LRP1B) in endometrial cancer, and analyze its association with lymph node metastasis (LNM) in endometrial cancer. Methods: Targeted next-generation sequencing (NGS) was conducted on both tumor tissues and paired blood DNA obtained from 94 endometrial cancer patients, followed by comprehensive analysis. Additionally, immunohistochemistry (IHC) was used to explore the correlation between LRP1B protein expression levels, its gene mutation status, and LNM. Results: LRP1B mutation was observed in 19 patients (20.2%). Our results revealed that LRP1B mutation frequencies were significantly different between endometrial cancer with or without LNM ( P = 0.038). Multivariate analysis indicated that LRP1B mutation was a favorable predictor (odds ratio 0.09; 95% confidence interval 0.01–0.95; P = 0.045) for LNM in endometrial cancer. Further analysis revealed that combination of LRP1B mutation with clinical variants (LVSI and histological subtype) yielded a higher area under the curve value of 0.871) and patients harboring LRP1B mutated-type were less likely to develop LNM. On integrated analysis, the concordance between LRP1B NGS and LRP1B IHC was 73.3%. Conclusions: This study utilizes targeted NGS to uncover the relationship between LRP1B mutation and LNM status, contributing to the development of primary prevention and proactive treatment strategies.
- Open Access
- 1 December 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 11437-11449
Nomogram Based on Immune-Inflammatory Score and Classical Clinicopathological Parameters for Predicting the Recurrence of Endometrial Carcinoma: A Large, Multi-Center Retrospective Study
Background: Surgery is the best approach to treat endometrial cancer (EC); however, there is currently a deficiency in effective scoring systems for predicting EC recurrence post-surgical resection. This study aims to develop a clinicopathological-inflammatory parameters-based nomogram to accurately predict the postoperative recurrence-free survival (RFS) rate of EC patients. Methods: A training set containing 1068 patients and an independent validation set consisting of 537 patients were employed in this retrospective study. The prognostic factors for RFS were identified by univariable and multivariable Cox proportional hazards regression analyses, and integrated into nomogram. The C-index, area under the curves (AUC), and calibration curves were employed to determine the predictive discriminability and accuracy of nomogram. Utilizing the nomogram, patients were stratified into low- and high-risk groups, and the Kaplan-Meier survival curve was further employed to assess the clinical efficacy of the model. Results: Cox regression analyses revealed that age (HR = 1.769, P = 0.002), FIGO staging (HR = 1.790, P = 0.018), LVSI (HR = 1.654, P = 0.017), Ca125 (HR = 1.532, P = 0.023), myometrial invasion (HR = 1.865, P = 0.001), cervical stromal invasion (HR = 1.655, P = 0.033), histology (HR = 2.637, P < 0.001), p53 expression (HR = 1.706, P = 0.002), PLR (HR = 1.971, P = 0.003), SIRI (HR = 2.187, P = 0.003), and adjuvant treatment (HR = 0.521, P = 0.003) were independent prognostic factors for RFS in patients with EC. A combined clinicopathologic-inflammatory parameters model was constructed, which outperformed the single-indicator model and other established models in predicting the 1-, 3-, and 5-year RFS rates in patients with EC. Conclusion: The nomogram demonstrated sufficient accuracy in predicting the RFS probabilities of EC, enabling personalized clinical decision-making for future clinical endeavors.
- 1 December 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 11437-11449
Open AccessNomogram Based on Immune-Inflammatory Score and Classical Clinicopathological Parameters for Predicting the Recurrence of Endometrial Carcinoma: A Large, Multi-Center Retrospective Study
Background: Surgery is the best approach to treat endometrial cancer (EC); however, there is currently a deficiency in effective scoring systems for predicting EC recurrence post-surgical resection. This study aims to develop a clinicopathological-inflammatory parameters-based nomogram to accurately predict the postoperative recurrence-free survival (RFS) rate of EC patients. Methods: A training set containing 1068 patients and an independent validation set consisting of 537 patients were employed in this retrospective study. The prognostic factors for RFS were identified by univariable and multivariable Cox proportional hazards regression analyses, and integrated into nomogram. The C-index, area under the curves (AUC), and calibration curves were employed to determine the predictive discriminability and accuracy of nomogram. Utilizing the nomogram, patients were stratified into low- and high-risk groups, and the Kaplan-Meier survival curve was further employed to assess the clinical efficacy of the model. Results: Cox regression analyses revealed that age (HR = 1.769, P = 0.002), FIGO staging (HR = 1.790, P = 0.018), LVSI (HR = 1.654, P = 0.017), Ca125 (HR = 1.532, P = 0.023), myometrial invasion (HR = 1.865, P = 0.001), cervical stromal invasion (HR = 1.655, P = 0.033), histology (HR = 2.637, P < 0.001), p53 expression (HR = 1.706, P = 0.002), PLR (HR = 1.971, P = 0.003), SIRI (HR = 2.187, P = 0.003), and adjuvant treatment (HR = 0.521, P = 0.003) were independent prognostic factors for RFS in patients with EC. A combined clinicopathologic-inflammatory parameters model was constructed, which outperformed the single-indicator model and other established models in predicting the 1-, 3-, and 5-year RFS rates in patients with EC. Conclusion: The nomogram demonstrated sufficient accuracy in predicting the RFS probabilities of EC, enabling personalized clinical decision-making for future clinical endeavors.
- Open Access
- 11 November 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1442489
A nomogram model to predict recurrence of early-onset endometrial cancer after resection based on clinical parameters and immunohistochemical markers: a multi-institutional study
Objective: This study aimed to investigate the prognosis value of the clinical parameters and immunohistochemical markers of patients with early-onset endometrial cancer (EC) and establish a nomogram to accurately predict recurrence-free survival (RFS) of early-onset EC after resection.Methods: A training dataset containing 458 patients and an independent testing dataset consisting of 170 patients were employed in this retrospective study. The independent risk factors related to RFS were confirmed using Cox regression models. A nomogram model was established to predict RFS at 3 and 5 years post-hysterectomy. The C-index, area under the curve (AUC) of the receiver operating characteristic (ROC) curve, and calibration curve were calculated to assess the predictive accuracy of the nomogram.Results: In all early-onset EC patients, more than half (368/628, 58.6%) were diagnosed in the age range of 45-49 years. Meanwhile, the recurrence rate of early-onset EC is approximately 10.8%. Multivariate Cox regression analyses showed that histological subtype, FIGO stage, myometrial invasion, lymphovascular space invasion (LVSI), P53 expression, and MMR status were independent prognostic factors related to RFS (all P < 0.05) and established the nomogram predicting 3- and 5-year RFS. The C-index and calibration curves of the nomogram demonstrated a close correlation between predicted and actual RFS. Patients were divided into high- and low-risk groups according to the model of RFS.Conclusions: Combining clinical parameters and immunohistochemical markers, we developed a robust nomogram to predict RFS after surgery for early-onset EC patients. This nomogram can predict prognosis well and guide treatment decisions.
- 11 November 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1442489
Open AccessA nomogram model to predict recurrence of early-onset endometrial cancer after resection based on clinical parameters and immunohistochemical markers: a multi-institutional study
Objective: This study aimed to investigate the prognosis value of the clinical parameters and immunohistochemical markers of patients with early-onset endometrial cancer (EC) and establish a nomogram to accurately predict recurrence-free survival (RFS) of early-onset EC after resection.Methods: A training dataset containing 458 patients and an independent testing dataset consisting of 170 patients were employed in this retrospective study. The independent risk factors related to RFS were confirmed using Cox regression models. A nomogram model was established to predict RFS at 3 and 5 years post-hysterectomy. The C-index, area under the curve (AUC) of the receiver operating characteristic (ROC) curve, and calibration curve were calculated to assess the predictive accuracy of the nomogram.Results: In all early-onset EC patients, more than half (368/628, 58.6%) were diagnosed in the age range of 45-49 years. Meanwhile, the recurrence rate of early-onset EC is approximately 10.8%. Multivariate Cox regression analyses showed that histological subtype, FIGO stage, myometrial invasion, lymphovascular space invasion (LVSI), P53 expression, and MMR status were independent prognostic factors related to RFS (all P < 0.05) and established the nomogram predicting 3- and 5-year RFS. The C-index and calibration curves of the nomogram demonstrated a close correlation between predicted and actual RFS. Patients were divided into high- and low-risk groups according to the model of RFS.Conclusions: Combining clinical parameters and immunohistochemical markers, we developed a robust nomogram to predict RFS after surgery for early-onset EC patients. This nomogram can predict prognosis well and guide treatment decisions.
- Open Access
- 19 April 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1338908
The prognostic value of co-expression of stemness markers CD44 and CD133 in endometrial cancer
Objective: The purpose of this study was to investigate the correlation between stemness markers (CD44 and CD133) and clinical pathological features, and to further explore the prognostic value of co-expression of CD44 & CD133 in endometrial cancer (EC).Methods: Clinical data of stage I-III EC patients who underwent initial surgical treatment at two large tertiary medical centers from 2015 to 2020 were retrospectively collected. Cohen’s kappa coefficient was used to show the consistency of the expression between CD44 and CD133. The correlation between co-expression of CD44 & CD133 and prognosis of EC patients was explored using univariate and multivariate Cox regression analysis. Then, the prognosis models for early-stage (stage I-II) EC patients were constructed. Finally, stratified analysis was performed for EC patients in high-intermediate-risk and high-risk groups, Kaplan-Meier analysis was used to compare the survival differences between patients with and without adjuvant therapy in different co-expression states (low expression, mixed expression, high expression) of CD44 & CD133.Results: A total of 1168 EC patients were included in this study. The consistency of the expression between CD44 and CD133 was 70.5%, the kappa coefficient was 0.384. High expression of CD44 & CD133 was associated with early FIGO stage (P=0.017), superficial myometrial invasion (P=0.017), and negative lymphatic vessel space invasion (P=0.017). Cox regression analysis showed that the co-expression of CD44 & CD133 was significantly correlated with the prognosis of early-stage (stage I-II) patients (P=0.001 for recurrence and P=0.005 for death). Based on this, the nomogram models were successfully constructed to predict the prognosis of early-stage EC patients. Meanwhile, Kaplan-Meier analysis showed that patients with adjuvant therapy had a better overall prognosis than those without adjuvant therapy in high-intermediate-risk and high-risk groups. However, there was no statistically significant difference in survival between patients with and without adjuvant therapy in high expression of CD44 & CD133 group (P=0.681 for recurrence, P=0.621 for death).Conclusion: High expression of CD44 & CD133 was closely related to the adverse prognosis of early-stage EC patients. Meanwhile, patients with high expression of CD44 & CD133 may not be able to achieve significant survival benefits from adjuvant therapy.
- 19 April 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1338908
Open AccessThe prognostic value of co-expression of stemness markers CD44 and CD133 in endometrial cancer
Objective: The purpose of this study was to investigate the correlation between stemness markers (CD44 and CD133) and clinical pathological features, and to further explore the prognostic value of co-expression of CD44 & CD133 in endometrial cancer (EC).Methods: Clinical data of stage I-III EC patients who underwent initial surgical treatment at two large tertiary medical centers from 2015 to 2020 were retrospectively collected. Cohen’s kappa coefficient was used to show the consistency of the expression between CD44 and CD133. The correlation between co-expression of CD44 & CD133 and prognosis of EC patients was explored using univariate and multivariate Cox regression analysis. Then, the prognosis models for early-stage (stage I-II) EC patients were constructed. Finally, stratified analysis was performed for EC patients in high-intermediate-risk and high-risk groups, Kaplan-Meier analysis was used to compare the survival differences between patients with and without adjuvant therapy in different co-expression states (low expression, mixed expression, high expression) of CD44 & CD133.Results: A total of 1168 EC patients were included in this study. The consistency of the expression between CD44 and CD133 was 70.5%, the kappa coefficient was 0.384. High expression of CD44 & CD133 was associated with early FIGO stage (P=0.017), superficial myometrial invasion (P=0.017), and negative lymphatic vessel space invasion (P=0.017). Cox regression analysis showed that the co-expression of CD44 & CD133 was significantly correlated with the prognosis of early-stage (stage I-II) patients (P=0.001 for recurrence and P=0.005 for death). Based on this, the nomogram models were successfully constructed to predict the prognosis of early-stage EC patients. Meanwhile, Kaplan-Meier analysis showed that patients with adjuvant therapy had a better overall prognosis than those without adjuvant therapy in high-intermediate-risk and high-risk groups. However, there was no statistically significant difference in survival between patients with and without adjuvant therapy in high expression of CD44 & CD133 group (P=0.681 for recurrence, P=0.621 for death).Conclusion: High expression of CD44 & CD133 was closely related to the adverse prognosis of early-stage EC patients. Meanwhile, patients with high expression of CD44 & CD133 may not be able to achieve significant survival benefits from adjuvant therapy.
- Open Access
- 2 April 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Knockdown of NCAPD3 inhibits the tumorigenesis of non-small cell lung cancer by regulation of the PI3K/Akt pathway
Background: Accumulating evidence indicates that aberrant non-SMC condensin II complex subunit D3 (NCAPD3) is associated with carcinogenesis of various cancers. Nevertheless, the biological role of NCAPD3 in the pathogenesis of non-small cell lung cancer (NSCLC) remains unclear. Methods: Immunohistochemistry and Western blot were performed to assess NCAPD3 expression in NSCLC tissues and cell lines. The ability of cell proliferation, invasion, and migration was evaluated by CCK-8 assays, EdU assays, Transwell assays, and scratch wound healing assays. Flow cytometry was performed to verify the cell cycle and apoptosis. RNA-sequence and rescue experiment were performed to reveal the underlying mechanisms. Results: The results showed that the expression of NCAPD3 was significantly elevated in NSCLC tissues. High NCAPD3 expression in NSCLC patients was substantially associated with a worse prognosis. Functionally, knockdown of NCAPD3 resulted in cell apoptosis and cell cycle arrest in NSCLC cells as well as a significant inhibition of proliferation, invasion, and migration. Furthermore, RNA-sequencing analysis suggested that NCAPD3 contributes to NSCLC carcinogenesis by regulating PI3K/Akt/FOXO4 pathway. Insulin-like growth factors-1 (IGF-1), an activator of PI3K/Akt signaling pathway, could reverse NCAPD3 silence-mediated proliferation inhibition and apoptosis in NSCLC cells. Conclusion: NCAPD3 suppresses apoptosis and promotes cell proliferation via the PI3K/Akt/FOXO4 signaling pathway, suggesting a potential use for NCAPD3 inhibitors as NSCLC therapeutics.
- 2 April 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Open AccessKnockdown of NCAPD3 inhibits the tumorigenesis of non-small cell lung cancer by regulation of the PI3K/Akt pathway
Background: Accumulating evidence indicates that aberrant non-SMC condensin II complex subunit D3 (NCAPD3) is associated with carcinogenesis of various cancers. Nevertheless, the biological role of NCAPD3 in the pathogenesis of non-small cell lung cancer (NSCLC) remains unclear. Methods: Immunohistochemistry and Western blot were performed to assess NCAPD3 expression in NSCLC tissues and cell lines. The ability of cell proliferation, invasion, and migration was evaluated by CCK-8 assays, EdU assays, Transwell assays, and scratch wound healing assays. Flow cytometry was performed to verify the cell cycle and apoptosis. RNA-sequence and rescue experiment were performed to reveal the underlying mechanisms. Results: The results showed that the expression of NCAPD3 was significantly elevated in NSCLC tissues. High NCAPD3 expression in NSCLC patients was substantially associated with a worse prognosis. Functionally, knockdown of NCAPD3 resulted in cell apoptosis and cell cycle arrest in NSCLC cells as well as a significant inhibition of proliferation, invasion, and migration. Furthermore, RNA-sequencing analysis suggested that NCAPD3 contributes to NSCLC carcinogenesis by regulating PI3K/Akt/FOXO4 pathway. Insulin-like growth factors-1 (IGF-1), an activator of PI3K/Akt signaling pathway, could reverse NCAPD3 silence-mediated proliferation inhibition and apoptosis in NSCLC cells. Conclusion: NCAPD3 suppresses apoptosis and promotes cell proliferation via the PI3K/Akt/FOXO4 signaling pathway, suggesting a potential use for NCAPD3 inhibitors as NSCLC therapeutics.
- 27 November 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 165 (2) , 655-665
Incidence, risk factors, and a prognostic nomogram for distant metastasis in endometrial cancer: A SEER‐based study
Objective: To evaluate the metastatic pattern, identify the risk factors, and establish a nomogram for predicting prognosis of endometrial cancer (EC) with distant metastasis.Methods: A retrospective cohort study of women diagnosed with EC was conducted according to the Surveillance, Epidemiology, and End Results (SEER) database during 2010–2017. Multivariate logistic analysis and Cox analysis were performed to identify the risk factors in promoting distant metastasis and predictors associated with overall survival (OS) in this particular subpopulation. A nomogram was then constructed and validated by the concordance index (C‐index), the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis.Results: A total of 2799 cases of distant metastasis in EC patients were identified, with an overall incidence rate of 3.74% from 2010 to 2017. Black race, unmarried status, non‐endometrioid histologic types, and grade IV were significant risk factors for distant metastasis in EC patients. Meanwhile, race, histology, grade, metastasis status, surgery, lymphadenectomy, and chemotherapy were identified as independent prognostic factors for OS. A nomogram to predict 1‐, 3‐, and 5‐year OS was established, and presented favorable accuracy and clinical applicability. Patients were further divided into high‐ and low‐risk groups according to the model.Conclusion: The nomogram was developed as a highly accurate, individualized tool to better predict the prognosis of EC patients with distant metastasis, which would help clinicians to identify high‐risk patients, and adjust and tailor their treatment strategies.
- 27 November 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 165 (2) , 655-665
Incidence, risk factors, and a prognostic nomogram for distant metastasis in endometrial cancer: A SEER‐based study
Objective: To evaluate the metastatic pattern, identify the risk factors, and establish a nomogram for predicting prognosis of endometrial cancer (EC) with distant metastasis.Methods: A retrospective cohort study of women diagnosed with EC was conducted according to the Surveillance, Epidemiology, and End Results (SEER) database during 2010–2017. Multivariate logistic analysis and Cox analysis were performed to identify the risk factors in promoting distant metastasis and predictors associated with overall survival (OS) in this particular subpopulation. A nomogram was then constructed and validated by the concordance index (C‐index), the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis.Results: A total of 2799 cases of distant metastasis in EC patients were identified, with an overall incidence rate of 3.74% from 2010 to 2017. Black race, unmarried status, non‐endometrioid histologic types, and grade IV were significant risk factors for distant metastasis in EC patients. Meanwhile, race, histology, grade, metastasis status, surgery, lymphadenectomy, and chemotherapy were identified as independent prognostic factors for OS. A nomogram to predict 1‐, 3‐, and 5‐year OS was established, and presented favorable accuracy and clinical applicability. Patients were further divided into high‐ and low‐risk groups according to the model.Conclusion: The nomogram was developed as a highly accurate, individualized tool to better predict the prognosis of EC patients with distant metastasis, which would help clinicians to identify high‐risk patients, and adjust and tailor their treatment strategies.